ArticleJournal of nanobiotechnology2026
Self-assembled nanoplatform for synergistic anti-angiogenic/photothermal therapy against gastric cancer with Src-mediated pathway blocking.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Anti-angiogenesis therapy has offered an innovative strategy to fight gastric cancer (GC) in the clinic. However, the systemic acquired resistance, low drug specificity, as well as diffusional hindrance of agents to the tumor site severely limit this mono-therapeutic method. To overcome the obstacles, we design and prepare a parallel targeted nanoplatform (Src-I1/CR NPs), which is self-assembled by Src kinase inhibitor (Src-I1) and near-infrared (NIR) phototherapeutic agent (CR) to fight GC. Under laser irradiation, the Src-I1/CR NPs can induce localized cellular apoptosis with mitochondrial and lysosomal damage, triggering excellent GC hyperthermia-ablation. Simultaneously, the nano-conjugate blocks the Src/STAT3/VEGF pathway to activate the anti-angiogenesis effect for tumor starving by inhibiting the supply of nutrients and oxygen. More importantly, Src-I1/CR NPs also restrain the Src-mediated PI3K/AKT pathway to comprehensively suppress cancer cell proliferation, invasion, and migration. Overall, multimodal NIR Src-I1/CR NPs initiate precise parallel targeting cancer cells with serious mitochondrial and lysosomal dysfunction as well as desired cellular apoptosis for augmented photo-ablation, which offers a promising avenue in further GC preclinical investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.